Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FGEN

FGEN - FibroGen Inc Stock Price, Fair Value and News

$8.43-0.10 (-1.17%)
Market Closed

25/100

FGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

25/100

FGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$7.31

Target 3M

$8.37

Target 6M

$7.77

FGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FGEN Price Action

Last 7 days

-4.4%

Last 30 days

1.8%

Last 90 days

-19.3%

Trailing 12 Months

-30.9%

FGEN RSI Chart

FGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FGEN Valuation

Market Cap

34.1M

Price/Earnings (Trailing)

0.16

Price/Sales (Trailing)

4.11

EV/EBITDA

1.96

Price/Free Cashflow

-2

FGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$7.31

Target 3M

$8.37

Target 6M

$7.77

FGEN Fundamentals

FGEN Revenue

Revenue (TTM)

8.3M

Rev. Growth (Yr)

774.8%

Rev. Growth (Qtr)

-20.18%

FGEN Earnings

Earnings (TTM)

215.7M

Earnings Growth (Yr)

1.3K%

Earnings Growth (Qtr)

2.7K%

FGEN Profitability

Operating Margin

167.09%

EBT Margin

-630.85%

Return on Equity

466.05%

Return on Assets

157.4%

Free Cashflow Yield

-50.12%

FGEN Investor Care

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

53.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.0M7.3M8.3M0
202442.5M38.2M33.9M29.6M
2023116.1M130.6M155.0M46.8M
2022257.7M263.1M122.9M140.7M
2021190.3M171.8M283.8M235.3M
2020257.1M108.4M119.3M176.3M
2019204.9M352.5M356.7M256.6M
2018133.5M147.2M135.6M213.0M
2017184.3M125.3M135.8M131.0M
2016192.8M161.5M172.1M183.2M
2015136.0M166.6M172.5M180.8M
2014111.0M119.9M128.7M137.6M
2013000102.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About FibroGen Inc

FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
 WEBSITEfibrogen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES592

FibroGen Inc Frequently Asked Questions

FGEN is the stock ticker symbol of FibroGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of FibroGen Inc is 34.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FGEN's fair value in chart for subscribers.

The fair value guage provides a quick view whether FGEN is over valued or under valued. Whether FibroGen Inc is cheap or expensive depends on the assumptions which impact FibroGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FGEN.

As of Tue Jan 27 2026, FGEN's PE ratio (Price to Earnings) is 0.16 and Price to Sales (PS) ratio is 4.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FGEN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, FibroGen Inc has provided -0.335 (multiply by 100 for percentage) rate of return.